CareDx Showcases Transplant Digital Leadership in Patient Care at 2022 MEET Conference

CareDx, Inc. (Nasdaq: CDNA) – The Transplant Company™ focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers – today announced that it is convening its annual digital health user conference, Management Expert Exchange in Transplantation (MEET), September 18-20 in Las Vegas, Nevada.

The CareDx user conference brings together transplant administrators, quality managers, transplant clinicians, and organ procurement organization professionals to showcase digital health innovations, share best practices, and discuss emerging trends surrounding transplant operations, quality improvement, patient management, and health equity. They will be led by an impressive set of speakers and panelists who will facilitate peer exchanges.

“Over the past few years, we have invested in patient-centered digital health solutions aimed at improving outcomes and the complex transplant journey,” said Reg Seeto, CEO and President of CareDx. “This dedication has resulted in CareDx becoming a leading provider of innovative solutions that empower patients and help the transplant community achieve operational efficiencies, quality measures, and equitable care for all patients.”

Yolanda Becker, MD, Director of Professional and Career Development at TCU School of Medicine, and former UNOS President, added, “Managing the process from initial referral to post-transplantation is complex, and we are extremely grateful for CareDx’s leadership in convening this annual meeting to share new ideas and solutions on our quest to provide high-quality patient care while navigating the realities of organ scarcity, operational fragmentation, and evolving quality standards.”

CareDx is a leading provider of digital health solutions that powerfully link participating transplant centers, healthcare providers, and patients in better navigating the complex transplant journey to improve patient care.

The AlloCare® mobile health app is fully integrated with AlloHome™ remote patient monitoring, TxAccess™ to manage the transplant waitlisting process, and medication adherence and education features that along with MedActionPlan® PRO streamline communications, facilitate earlier interventions, and empower patients to take greater control of their care. Data and workflow management software ensure that CareDx testing services easily integrate with electronic medical records (EMR) and other transplant platforms like Ottr® and TransChart®, and XynQAPI® quality management software helps transplant centers achieve operational efficiencies.

The topics of discussion during the 2022 MEET Conference include:

• Review of the recent National Academies of Sciences, Engineering, and Medicine (NASEM) report, “Realizing the Promise of Equity in the Organ Transplantation System,” and how centers can put these recommendations into action
• Addressing health disparities in transplantation
• Patients taking charge of their health using technology
• Panel discussions on improving the referral to waitlist process, reducing readmissions and length of stay, and reducing staff burnout

About CareDx – The Transplant Company

CareDx, Inc., headquartered in Brisbane, California, is a leading precision medicine solutions company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers. CareDx offers testing services, products, and digital healthcare solutions along the pre- and post-transplant patient journey and is the leading provider of genomics-based information for transplant patients. For more information, please visit: www.CareDx.com.

Forward Looking Statements

This press release includes forward-looking statements related to CareDx, Inc., including statements regarding the potential benefits and results that may be achieved with CareDx’s digital health solutions, including the AlloCare mobile health app, and CareDx’s convening of the 2022 MEET digital health conference (the “Conference”). These forward-looking statements are based upon information that is currently available to CareDx and its current expectations, speak only as of the date hereof, and are subject to risks and uncertainties that could cause actual results to differ materially from those projected, including risks that CareDx does not realize the expected benefits of its digital health solutions, including the AlloCare mobile health app, and convening the Conference; risks that the Conference fails to take place at the time and place or discuss the topics as shown in the press release; general economic and market factors; and other risks discussed in CareDx’s filings with the SEC, including the Annual Report on Form 10-K for the fiscal year ended December 31, 2021 filed by CareDx with the SEC on February 24, 2022, the quarterly report on Form 10-Q for the quarter ended March 31, 2022 filed by CareDx with the SEC on May 5, 2022, the quarterly report on Form 10-Q for the quarter ended June 30, 2022 filed by CareDx with the SEC on August 4, 2022, and other reports that CareDx has filed with the SEC. Any of these may cause CareDx’s actual results, performance, or achievements to differ materially and adversely from those anticipated or implied by CareDx’s forward-looking statements. CareDx expressly disclaims any obligation, except as required by law, or undertaking to update or revise any such forward-looking statements.

View source version on businesswire.com: https://www.businesswire.com/news/home/20220919005312/en/